Skip to main content
. 2023 Jan 9;22:3. doi: 10.1186/s12943-022-01711-9

Table 1.

Patient characteristics

Patient No. Age (y)
/Sex
Diagnosis Prior Treatment CAR-T Cells Dose and Routes
Surgery Radiation
+ TMZ
IDH1/2 MGMT GD2 Intensity
01 63/F GBM Yes,×2 TMZ, No Radiation WT UM 4.0+

i.v. 1.3 × 108

i.c. 5 × 106

02 4/M GBM Yes,×2 Radiation, No TMZ WT UM 3.0+

i.v. 6.4 × 107

i.c. 2.6 × 106

03 6/F GBM Yes Yes WT UM 2.0+ i.v. 4.6 × 107
04 38/F GBM Yes Yes WT UM 2.5+ i.v. 1.4 × 108
05 29/M GBM Yes,×2 Yes WT ML 2.0+

i.v. 1.6 × 108

i.c. 6.4 × 106

06 3/M GBM Yes Radiation, No TMZ WT UM 3.5+ i.v. 3.8 × 107
07 5/F GBM Yes Radiation, No TMZ WT UM 1.5+ i.v. 3 × 107
08 31/M GBM Yes Yes WT UM 3.5+ i.v. 2.1 × 108

TMZ Temozolomide, WT Wildtype, UM Unmethylated, ML Methylated, i.v. Intravenous, i.c. Intracavitary